Furthermore, IHC assays revealed that SLC25A21 protein expression was heterogeneous and confirmed a significant decrease in the SLC25A21 protein level in both KRAS-mutant and KRAS-WT CRC tissues (P < 0.01, Figure 1F), but no significant differences were found between the 2 groups of CRC tissues (P = 0.1641). This evidence concerns the gene KRAS and colorectal carcinoma.